Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant

The Metroticket 2.0 model was proposed as an accurate predictor of “tumor-related death” occurring for hepatocellular carcinoma recurrence after liver transplantation. The present study shows that its accuracy can be improved, in candidates receiving neo-adjuvant therapies, through incorporation of mRECIST radiological response, providing refined criteria for t ransplantability of HCCs.

Source: Journal of Hepatology - March 18, 2020 Category: Gastroenterology Authors: Alessandro Cucchetti, Matteo Serenari, Carlo Sposito, Stefano Di Sandro, Cristina Mosconi, Ilaria Vicentin, Enrico Garanzini, Vincenzo Mazzaferro, Luciano De Carlis, Rita Golfieri, Carlo Spreafico, Angelo Vanzulli, Vincenzo Buscemi, Matteo Ravaioli, Giorg Source Type: research